ANSLY:OTC-Ansell Limited (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC

Last Closing Price

USD 96.20

Change

0.00 (0.00)%

Market Cap

USD 3.06B

Volume

579.00

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables used by hospitals, surgical centers, dental practices, veterinary clinics, first responders, laboratories, and life sciences and pharmaceutical companies. The Industrial segment manufactures and markets hand and chemical protective clothing solutions for a range of industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, and first responders. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-24 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ESLOY EssilorLuxottica Société ano..

N/A

USD88.01B 56.54 21.02
ESLOF EssilorLuxottica Société ano..

N/A

USD87.92B 56.49 21.02
HOCPF HOYA Corporation

N/A

USD57.12B 47.05 0.24
HOCPY HOYA Corporation

N/A

USD56.23B 46.32 0.24
SDMHF Sartorius Stedim Biotech S.A

N/A

USD51.33B 82.73 56.51
SUVPF Sartorius Aktiengesellschaft

N/A

USD45.54B 188.27 45.93
SARTF Sartorius Aktiengesellschaft

N/A

USD45.54B 209.43 45.93
RSMDF ResMed Inc

N/A

USD38.98B 30.94 34.52
CLPBY Coloplast A/S

N/A

USD35.23B 49.40 5.05
CLPBF Coloplast A/S

N/A

USD35.13B 49.48 5.05

ETFs Containing ANSLY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.36% 42% F 35% F
Dividend Return 2.96% 85% B 47% F
Total Return -4.40% 41% F 36% F
Trailing 12 Months  
Capital Gain -7.36% 39% F 29% F
Dividend Return 2.96% 90% A- 38% F
Total Return -4.40% 40% F 29% F
Trailing 5 Years  
Capital Gain 37.61% 37% F 59% F
Dividend Return 12.33% 71% C- 40% F
Total Return 49.94% 35% F 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 14.70% 25% F 52% F
Dividend Return 1.95% 80% B- 44% F
Total Return 16.65% 23% F 52% F
Risk Return Profile  
Volatility (Standard Deviation) 22.78% 86% B 77% C+
Risk Adjusted Return 73.09% 67% D+ 91% A-
Market Capitalization 3.06B 57% F 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 12.68 84% B 55% F
Price/Book Ratio 2.01 80% B- 46% F
Price / Cash Flow Ratio 17.72 36% F 13% F
EV/EBITDA 8.32 58% F 38% F
Management Effectiveness  
Return on Equity 16.78% 62% D- 81% B-
Return on Invested Capital 10.86% 72% C- 74% C
Return on Assets 7.97% 75% C 90% A-
Debt to Equity Ratio 29.12% 43% F 49% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.41 52% F 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector